Company Description
SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. We have developed a powerful, new Drug Delivery Platform (SDP) that will revolutionize how safe and promising, yet challenged drugs, can be delivered to kill cancer. SciTech has developed our first, patented drug, ST-001-nanoFenretinide that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. SciTech’s innovations will impact our mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. SciTech Development is in the pre-revenue clinical stage of development.
Perks
StartEngine OWNERS Exclusive Click here to learn more
$275+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
Week 1
Invest within the 1st week and receive 20% bonus shares.
6
days
7
hours
51
mins
55
secs
$500+ Investment
Tier 1
Invest >$500, you will receive 5% bonus shares.
$1,500+ Investment
Tier 2
If you invest >$1,500, you will receive 10% bonus shares.
$5,000+ Investment
Tier 3
If you invest >$5,000, you will receive 15% bonus shares.
$10,000+ Investment
Tier 4
If you invest >$10,000, you will receive 20% bonus shares and an in-person** or virtual meeting with the leadership team.
Key Deal Facts
SDP, our proprietary and revolutionary Drug Delivery Platform, has enormous potential to develop and deliver new and better drugs for incurable cancers.
ST-001 (SDP plus fenretinide) is patented and clinical trial ready, with an FDA guided accelerated trial plan. Fenretinide presents a low risk scenario since it has been shown to be safe and effective in both children and adults. ST-001 is an affordable, cost-effective cancer treatment.
The market potential for ST-001 is about $2B, with an additional $5B-25B+ market potential from other targeted cancer indications, ST-001 combination therapies and from using our Delivery Platform to engineer and patent new drugs.
Management Team / Advisory Board Bios
Earle Holsapple
CEO, President & Co-Founder
Mr. Holsapple has extensive managerial experience spanning many decades in a wide host of industries. He has successfully served as CEO/COO of six profitable midsize industrial or consumer products companies ranging in size from $10M to $100M in sales. He has managed four corporate turnarounds restoring each company to financial health. As an entrepreneur, he has started four new companies ranging in focus from international trade to complex life science startups. He previously served his country as an air defense officer in the United States Marine Corps rising to the rank of Captain.
Andrew Stumpf
Chief Financial Officer (CFO)
Mr. Stumpf brings 20+ years of experience as a finance professional in private equity, investment banking, corporate finance, and public accounting. Mr. Stumpf serves on the board of directors of a public diversified holding company as a member on the audit, compensation and nominating committees. Mr. Stumpf is a partner with Storm Lake Capital, a private equity firm that invests in middle market companies. Mr. Stumpf also performs in a finance capacity for several portfolio companies with responsibilities including financial and strategic planning and budgeting, financial reporting and year-end audit and tax filings.
Louis M. Scarmoutzos, Ph.D.
Chief Operating Officer
Dr. Scarmoutzos has over 30 years of industrial experience in the biotech, chemistry, healthcare, medical device, pharmaceutical, and related industries. His hands-on industrial experience ranges from Bench Top Scientist to Vice President of R&D to President and CEO. He has founded several companies and is currently a Board Member of several small and emerging companies. Dr. Scarmoutzos received his B.S. cum laude in Chemistry from Boston College, a Ph.D. summa cum laude in Organic Chemistry from the Pennsylvania State University and was a Post-Doctoral Fellow in the Department of Chemistry and Chemical Biology at Harvard University.
Ralph Parchment, Ph.D.
Chief Scientific Advisor & Co-Founder
Dr. Parchment is an accomplished pharmacologist and the principal inventor of the SciTech drug delivery technology. He presently directs a multi-laboratory program at the Frederick National Laboratory for Cancer Research where he manages the effort to create innovative approaches for evaluating and developing new drug compounds. He has worked part-time supporting SciTech’s development, patenting and commercialization activities. He brings a wealth of knowledge, in the field of oncology drug development, to bear on SciTech’s behalf. He invented ST-001 while on the faculty of Wayne State University where he was a core leader for the Karmanos Cancer Institute (KCI).
Michael Burns, Ph.D.
Product Development
Dr. Burns has nearly 40 years of pharmaceutical industry experience; Past CEO of Ferndale Pharma Group which comprises companies that specialize in the development, manufacture, marketing, sale and distribution of a wide variety of healthcare products. Dr. Burns was also CEO of Repromedix Corp, a life science company providing advanced testing and advisory services in reproductive medicine. He was instrumental in the divestment of ReproSource, Inc. Dr. Burns is an advisor to startup companies in oncology, skin care, and reproductive medicine.
Ali Moiin, M.D.
Clinical Affairs
Dr. Moiin is board certified in Dermatology and is a practicing Dermatologist. He has an extensive background in treating patients with cutaneous T-cell lymphoma (CTCL) and is a lead researcher for ST-001 as a topical therapeutic. He maintains affiliations with major medical centers in the Detroit metro area, including Detroit Medical Center, St. John's Hospital, St. Mary's Hospital and William Beaumont Hospital. Dr. Moiin received his bachelor's degree in pharmacology and master's degree in biology from the University of California, Santa Barbara. He was awarded his Doctor of Medicine degree from the University of California, Davis.
David R. Schaffer
Investor Relations
Mr. Schaffer has 30 years of experience in global equity capital markets, investment banking, equity market research, investor relations and strategic advisory to public/private funds. His skills include P&L accountability, customer retention, collaborative product development, business planning across diverse global markets resulting in increased bottom-line and market share growth. Mr. Schaffer has held executive positions at Raymond James Global Equity Markets, Kaufman, Advest and BD/M Collective.